Microglial activation correlates with severity in Huntington disease: A clinical and PET study

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • N. Pavese
  • A. Gerhard, Hammersmith Hospital
  • ,
  • Y. F. Tai, Hammersmith Hospital
  • ,
  • A. K. Ho, University of Cambridge, School of Clinical Medicine
  • ,
  • F. Turkheimer, Hammersmith Hospital
  • ,
  • R. A. Barker, University of Cambridge, School of Clinical Medicine
  • ,
  • D. J. Brooks
  • P. Piccini, Hammersmith Hospital

BACKGROUND: Huntington disease (HD) is characterized by the progressive death of medium spiny dopamine receptor bearing striatal GABAergic neurons. In addition, microglial activation in the areas of neuronal loss has recently been described in postmortem studies. Activated microglia are known to release neurotoxic cytokines, and these may contribute to the pathologic process. METHODS: To evaluate in vivo the involvement of microglia activation in HD, the authors studied patients at different stages of the disease using [C](R)-PK11195 PET, a marker of microglia activation, and [C]raclopride PET, a marker of dopamine D2 receptor binding and hence striatal GABAergic cell function. RESULTS: In HD patients, a significant increase in striatal [C](R)-PK11195 binding was observed, which significantly correlated with disease severity as reflected by the striatal reduction in [C]raclopride binding, the Unified Huntington's Disease Rating Scale score, and the patients' CAG index. Also detected were significant increases in microglia activation in cortical regions including prefrontal cortex and anterior cingulate. CONCLUSIONS: These [C](R)-PK11195 PET findings show that the level of microglial activation correlates with Huntington disease (HD) severity. They lend support to the view that microglia contribute to the ongoing neuronal degeneration in HD and indicate that [C](R)-PK11195 PET provides a valuable marker when monitoring the efficacy of putative neuroprotecting agents in this relentlessly progressive genetic disorder.

Original languageEnglish
Pages (from-to)1638-1643
Number of pages6
Publication statusPublished - 1 Jun 2006
Externally publishedYes

See relations at Aarhus University Citationformats

ID: 131159933